Becton Dickinson and Co

Becton Dickinson and Co(BDX)股票分析

$191.750

-1.994 (-1.04%)收盤時

Loading chart…
最高
195.990
開盤
194.420
成交量加權均價
192.65
成交量
1.41M
市值
66.74B
最低
190.210
成交金額
272.15M
企業價值/稅息折舊攤銷前利潤(TTM)
12.68

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences.

AI 分析 of Becton Dickinson and Co (BDX)

買進

Becton Dickinson (BDX) is a good buy right now due to its current price of $191.75, which is below the average analyst price target of $200, suggesting potential upside. The stock has a strong gross margin of 46.76% and a forward P/E ratio of 13.72, indicating solid profitability and reasonable valuation. However, the main risk is the recent dip in net income, with a reported loss of $31 million in Q2 2026, which could impact future performance.

分析師評級(15)

上檔空間 +0.46%
買進
10 買進
5 持有
0 賣出
目前: 191.75
最低
157.00
平均
192.64
最高
232.00

Barclays

2026-10-07

目標價

$165

減持

BofA

2026-08-31

目標價

$200

中性

RBC Capital

2026-08-13

目標價

$190

Sector Perform

Citi

2026-08-13

目標價

$208

買進

RBC Capital

2026-08-07

目標價

$180

Sector Perform

估值指標

Becton Dickinson and Co(BDX)目前預期本益比為 13.72,5 年平均預期本益比為 17.19。

預期本益比

合理
5 年均值 P/E
17.19
目前P/E
13.72
高估
20.85
低估
13.52

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
14.11
目前EV/EBITDA
12.68
高估
16.40
低估
11.82

預期股價營收比

合理
5 年均值 P/S
3.18
目前P/S
2.67
高估
3.76
低估
2.59

Alphio AI 對 BDX 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%BDX

$193.53

情境價格

基

基準

基準 · 50%BDX

$172.62

情境價格

悲

悲觀

悲觀 · 25%BDX

$171.68

情境價格

持有 BDX 的大戶

J

John W. Bristol & Co., Inc.

+ 持有BDX

+6.49%

3個月報酬率

V

Veritas Asset Management LLP

+ 持有BDX

+5.30%

3個月報酬率

J

James Hambro & Partners LLP

+ 持有BDX

+4.65%

3個月報酬率

B

Beutel Goodman & Company Ltd.

+ 持有BDX

+4.35%

3個月報酬率

F

Fort Washington Investment Advisors, Inc.

+ 持有BDX

+4.29%

3個月報酬率

G

Guyasuta Investment Advisors, Incorporated

+ 持有BDX

+3.73%

3個月報酬率

事件時間軸

2026-10-07 (ET)

08:30:00

BD Reports Positive Nine-Month Results for Revello Vascular Covered Stent

2026-10-06 (ET)

07:00:00

Becton Dickinson Partners with U.S. Government for $19B Manufacturing Expansion

2026-09-21 (ET)

17:00:00

Becton, Dickinson Appoints Arthur Hu as Chief Information Officer

2026-08-12 (ET)

07:00:00

Becton Dickinson Completes Enrollment in PREVENT Clinical Trial

資訊

BDX 常見問題 —— 由 Alphio AI 解答

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Becton Dickinson (BDX) is a good buy right now due to its current price of $191.75, which is below the average analyst price target of $200, suggesting potential upside. The stock has a strong gross margin of 46.76% and a forward P/E ratio of 13.72, indicating solid profitability and reasonable valuation. However, the main risk is the recent dip in net income, with a reported loss of $31 million in Q2 2026, which could impact future performance.

15 analysts cover BDX: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 192.64.

range_bonder2026/9/16

Beldex @BeldexCoin recently published two research pieces, and I think they are interesting to look at together. One is about age verification: you only need to prove you are over 18, without handing over your birthday, identity, and nationality all at once. At the same time, it checks that the credential signature is real, that the age is actually derived from that birthday, that the same number is locked in the commitment, and that this number is not below 18. In the end, the other party only gets one result: you meet the age requirement. This is still research for now. Beldex Research Labs is next trying Bulletproof to make the proof smaller and push verification cost down further. It has not yet become a ready feature in BChat or the wallet. The other is VRF consensus. Beldex's current PoS already has a layer of random validator selection. What VRF aims to add is verifiable randomness: everyone can later verify whether the result of who got selected followed the rules, while before the draw it is harder to predict in advance who the next batch will be. The team currently places the VRF-based PoS hardfork in Q1 2027. This is also a later upgrade, not something already fully switched over on mainnet now. One is dealing with how much identity information should be exposed, and the other is dealing with how randomness in consensus should be proven. These two research lines at Beldex are actually quite consistent in direction: provide enough information, and avoid exposing extra information as much as possible.

展開
註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易